765 860
Chaple 2013,
[35]
Mirabegron
25 mg
Age 18,
OAB symptoms
3 mo,
3 urgency
episodes
12 wk 333
a ,men 35,
(10.5)
women 298,
(89.5)
57.2 12.1
(NA)
145 –0.52, 1.3
57.1 12.9,
(NA)
144
–0.44, 1.1
–0.08,
(–0.36, 0.2)
Mirabegron 25 mg is
not superior to
placebo
Chaple 2013,
[35]
Mirabegron
50 mg
Age 18,
OAB symptoms
3 mo,
3 urgency
episodes
12 wk 333
a ,men 33,
(10)
women 300,
(90)
56.9 12.5
(NA)
142 –0.6, 1.3
57.1 12.9,
(NA)
144
–0.44, 1.1
–0.16,
(–0.44, 0.12)
Mirabegron 50 mg is
superior to placebo
Chaple 2013,
[35]
Mirabegron
100 mg
Age 18, OAB
symptoms
3 mo,
3 urgency
episodes
12 wk 334
a ,men 32,
(9.5)
women 302,
(90.5)
57.1 12.5
(NA)
141 –0.42, 1.3
57.1 12.9,
(NA)
144
–0.44, 1.1
0.02,
(–0.26, 0.30)
Mirabegron 100 mg is
not superior to
placebo
Chaple 2013,
[35]
Mirabegron
200 mg
Age 18,
OAB symptoms
3 mo,
3 urgency
episodes
12 wk 332
a ,men 27,
(8)
women 305,
(92)
58.0 13.7
(NA)
147 –0.59, 1.3
57.1 12.9,
(NA)
144
–0.44, 1.1
–0.15,
(–0.43, 0.13)
Mirabegron 200 mg is
not superior to
placebo
Chaple 2013,
[35]
Tolterodine
ER 4 mg
Age 18, OAB
symptoms
3 mo,
3 urgency
episodes
12 wk 251
a ,men 31,
(12.4)
women 220,
(87.6)
56.6 12.8
(NA)
72 –0.59, 1.2
57.1 12.9,
(NA)
144
–0.44, 1.1
–0.15,
(–0.49, 0.19)
Tolterodine ER 4 mg is
not superior to
placebo
Drake 2004,
[50]
Melatonin
2 mg
Menwith IPSS
Q7 score 3
4 wk 20,
men 20, (100)
women (0)
72.2 NA
(60–81)
19 –0.3, 0.9
72.2 NA,
(60–81)
19
–0.1, 0.1
–0.20,
(–0.61, 0.21)
Melatonin
significantly improves
nocturia response rate
Reynard 1988,
[42]
Furosemide
40 mg
Age 50,
NP
4 wk 49,
men 49, (100)
women (0)
70 NA
(NA)
23 –0.5, na
69 NA,
(NA)
20
0, NA
Not estimable Furosemide improves
nocturnal frequency
in NP patients
Yokoyama 2014,
[31]
Fesoterodine
4 mg
Nocturia 2,
8 voiding,
1 urgency
episodes
12 wk 354
a ,men 88, (25)
women 266 (75)
62.0 13.5
(27–86)
180 –0.63, 1.42 59.7 14, (27–88)
174
–0.56, 1.45 –0.07,
(–0.37, 0.23)
Fesoterodine reduces
nocturnal frequency
Yokoyama 2014,
[31]
Fesoterodine
8 mg
Nocturia 2,
8 voiding,
1 urgency
episodes
12 wk 375
a ,men 90, (24)
women 285 (76)
60.6 14
(20–87)
201 –0.77, 1.34 59.7 14, (27–88)
174
–0.56, 1.45 –0.07,
(–0.37,0.23)
Fesoterodine reduces
nocturnal frequency
Oelke 2014,
[36]Dutasteride
0.5 mg
BPH, IPSS 12,
PSA: 1.5–10,
flow: 15 ml/s
12 mo 4244,
men 4244, (100)
women (0)
NA
2121 –0.28, 0.04 NA
2123
–0.11, 0.05 –0.17,
(–0.17, –0.17)
Dutasteride improves
nocturia outcomes
based on IPSS
Question 7 Score
Adla 2006,
[44]
Diclofenac
50 mg
Nocturia 2, NP
5 wk 26,
men 20, (77)
women 6, (23)
72 NA
(52–90)
26 –0.5, 0.23
72 NA,
(52–90)
26
–0.1, 0.23
–0.40,
(–0.53, –0.27)
Diclofenac reduces
mean nocturnal
frequency
Falahaktar 2008,
[45]
Celecoxib
100 mg
BPH, 2 voids
per night,
IPSS 8,
NP excluded
1 mo 80,
men 80, (100)
women (0)
64.3 7.7
(49–80)
40 –2.67, 0.2
64.9 7.05, (50–80)
40
–0.18, 0.5
–2.49,
(–2.66, –2.32)
Celecoxib reduces
mean nocturnal
frequency
Cannon 1999,
[18]
Desmopressin
20
m
g
NP
7 wk 18,
men 80, (100)
women (0)
70.5 NA
(52–80)
18 –0.3, 0.45
70.5 NA,
(52–80)
18
0.1, 0.69
–0.40,
(–0.78, –0.02)
Improvement in
nocturnal volume.
Cannon 1999,
[18]
Desmopressin
40
m
g
NP
7 wk 18,
men 18, (100)
women (0)
70.5 NA
(52–80)
18 –0.7, 0.39
70.5 NA,
(52–80)
18
0.1, 0.69
–0.8,
(–1.16, –0.44)
Improvement in
nocturnal volume and
nocturnal frequency
BPH = benign prostatic hyperplasia; CI = confidence interval; ER = extended release; IPSS = International Prostate Symptom Score; IV = independent variable; LUTS = lower urinary tract symptoms; NA = not available;
NP = nocturnal polyuria; OAB = overactive bladder; SD = standard deviation.
a
Data modified for the purposes of the table.
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 7 5 7 – 7 6 9
765